{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:44Z","timestamp":1790717144881,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012020"],"award-info":[{"award-number":["2022A1515012020"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073431"],"award-info":[{"award-number":["82073431"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872524"],"award-info":[{"award-number":["81872524"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.anai.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T13:57:13Z","timestamp":1652968633000},"page":"360-365.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.1016","volume":"129","author":[{"given":"Cui-Cui","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Chen","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Chi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Qiu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Zhen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Qin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-2751","authenticated-orcid":false,"given":"Liangchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2022.05.009_bib0002","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J Dermatol"},{"issue":"10106","key":"10.1016\/j.anai.2022.05.009_bib0003","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0004","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1071","article-title":"The medication risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.anai.2022.05.009_bib0006","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2022.05.009_bib0008","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0009","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/1346-8138.13040","article-title":"Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis: a retrospective study","volume":"43","author":"Choonhakarn","year":"2016","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2022.05.009_bib0010","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.anai.2022.05.009_bib0011","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/ajd.12462","article-title":"Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"58","author":"Yang","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.anai.2022.05.009_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-alpha and CCL27 in serum and blister of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2022.05.009_bib0014","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2022.05.009_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/jdv.16685","article-title":"Systemic therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a SCORTEN-based systematic review and meta-analysis","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0018","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2022.05.009_bib0019","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1684\/ejd.2020.3883","article-title":"A new case series on etanercept treatment for toxic epidermal necrolysis","volume":"30","author":"Paradisi","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2022.05.009_bib0020","doi-asserted-by":"crossref","first-page":"e12832","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.anai.2022.05.009_bib0021","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/1346-8138.15058","article-title":"Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap with etanercept: a case report and published work review","volume":"46","author":"Wang","year":"2019","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.anai.2022.05.009_bib0022","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1111\/jdv.15006","article-title":"The therapeutic potential of TNF-\u03b1 antagonists in toxic epidermal necrosis: insights from two cases and adverse event reports","volume":"32","author":"Vural","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.anai.2022.05.009_bib0023","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0024","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2022.05.009_bib0025","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/j.jaad.2013.07.036","article-title":"Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases","volume":"69","author":"Napolitano","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0027","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 7","key":"10.1016\/j.anai.2022.05.009_bib0028","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.4103\/0378-6323.115526","article-title":"Tumor necrosis factor-\u03b1 antagonists: side effects and their management","volume":"79","author":"Dogra","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.anai.2022.05.009_bib0029","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4103\/0378-6323.191134","article-title":"Guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis: an Indian perspective","volume":"82","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"10.1016\/j.anai.2022.05.009_bib0030","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.burns.2018.12.018","article-title":"Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"45","author":"Pham","year":"2019","journal-title":"Burns J Int Soc Burn Inj"},{"issue":"6","key":"10.1016\/j.anai.2022.05.009_bib0031","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jaad.2022.01.039","article-title":"Inhibition of tumor necrosis factorimproves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","volume":"86","author":"Ao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0032","first-page":"247","article-title":"Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017","volume":"182","author":"Bettuzzi","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2022.05.009_bib0033","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaip.2017.02.013","article-title":"Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study","volume":"5","author":"Dibek Misirlioglu","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.05.009_bib0034","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jaip.2018.05.024","article-title":"A retrospective cohort study of the management and outcomes of children hospitalized with Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"7","author":"Antoon","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2022.05.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3061084","article-title":"Clinical features and treatment outcomes among children with Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year study in a tertiary referral hospital","volume":"2018","author":"Chatproedprai","year":"2018","journal-title":"Dermatol Res Pract"},{"issue":"5","key":"10.1016\/j.anai.2022.05.009_bib0036","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/1203475419861078","article-title":"Pediatric SJS\/TEN subdued by a combination of dexamethasone, cyclosporine, and etanercept","volume":"23","author":"Coulombe","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.anai.2022.05.009_bib0037","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/1203475418758989","article-title":"Pediatric Stevens-Johnson syndrome\/toxic epidermal necrolysis halted by etanercept","volume":"22","author":"Gavigan","year":"2018","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"10.1016\/j.anai.2022.05.009_bib0038","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamadermatol.2019.3731","article-title":"Use of etanercept in a series of pediatric patients with Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum disease","volume":"156","author":"Eliades","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2022.05.009_bib0039","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/1759-7714.13275","article-title":"Management of immune checkpoint inhibitor-related dermatologic adverse events","volume":"11","author":"Si","year":"2020","journal-title":"Thorac Cancer"},{"issue":"8","key":"10.1016\/j.anai.2022.05.009_bib0040","first-page":"e9587","article-title":"Immune-mediated toxic epidermal necrolysis","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622004410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622004410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:23:13Z","timestamp":1778588593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622004410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1081120622004410"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.05.009","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}